POCT INR
[POCT INR]
EPTIS Ringversuch Nr. 142678 | Letze Änderung 2024-05-21 | URL: https://www.eptis.bam.de/pts142678 https://www.eptis.bam.de/pts142678
| Name des Anbieters | |||||||
| Name des Anbieters | Weqas Weqas | ||||||
| Ansässig in | United Kingdom | ||||||
| Sprache(n) | |||||||
| Anmerkungen | Patients receiving warfarin, a Vitamin K antagonist (VKA) as anticoagulant therapy will have their International normalized ratio (INR) measured regularly to ensure that their medication is effective, and the dose adjusted accordingly to maintain the INR within the appropriate range. Warfarin, the most commonly used VKA, is a coumarin derivative that acts by inhibiting vitamin K dependent clotting factors (II, VII, IX, X) in addition to the anticoagulant proteins C and S. The INR calculation is based on a standardised ratio of the patient’s Prothrombin time, (PT) versus a normal control sample. Therefore, the INR of a healthy individual not on anticoagulation therapy would be 1.0. PT measures the time taken (in seconds) for the blood to clot following addition of thromboplastin, an activating enzyme. Warfarin is licensed for prophylaxis of embolization in rheumatic heart disease and atrial fibrillation, prophylaxis after insertion of prosthetic heart valve, prophylaxis and treatment of venous thrombosis (DVT), pulmonary embolism (PE), and in transient ischaemic attacks. The programme includes a panel of samples spanning the pathological range, however the majority of samples distributed in the year are specifically selected to challenge the therapeutic targets of 2.5 and 3.5. One liquid stable sample is distributed every 2 months, a minimum of six samples per year, some of which are distributed on a number of occasions. This allows for the assessment of the organisation’s and method’s performance, including linearity, bias, within and between batch imprecision. Key Features: - Stable samples supplied ready to use, no pre-analytical preparation is required. - Panel of samples distributed over the year that spans the therapeutic target ranges. - Scoring based on Milan Model 3 performance specification. For more information: https://www.weqas.com/services/poct-eqa/poct-inr/ or contact@weqas.com | ||||||
| Klassifizierung | |||||||
| Produktgruppen |
Health care / medical devices
|
||||||
| Prüfgebiete |
Medical analysis
|
||||||
| Technische Einzelheiten | |||||||
|
|||||||
| Ringversuchsziele | |||||||
| Zielgruppe des Ringversuchs | Laboratory Diagnostic Services and Point of Care Testing Services. The INR EQA control material is suitable for use with the majority of POCT devices including the Abbott-i-STAT, the Roche CoaguChek range of devices, and the Siemens Xprecia Stride. | ||||||
| Relevante Rechtsvorschriften oder Normen | Accreditation by UKAS on the basis of ISO/IEC 17025, 17043 and 15195 | ||||||
| Weitere Ziele | validation of testing methods | ||||||
| Teilnehmerzahl | |||||||
| Anbieter unabhängig überprüft (akkreditiert, benannt, anerkannt) |
Akkreditiert durch UKAS auf der Grundlage von ISO/ IEC 17043 |
||||||
| Die Durchführung des Ringversuchs ist in Auftrag gegeben durch | |||||||
| Kosten | |||||||
| Teilnahmegebühr | https://www.weqas.com/participantzone/subscription-charges/ | ||||||
| Regelmässig durchgeführt | Ja (Frequency: Bimonthly. Samples: 1 x 0.3mL) | ||||||
| Der Ringversuch wird durchgeführt seit | 2009 | ||||||
| Kontaktdaten des Anbieters | |||||||
| Anbieter | Kontaktperson | ||||||
|
Weqas
Unit 6, Parc Ty Glas CF14 5DU Cardiff United Kingdom Telefon: 44 (0) 2920 314750 Fax: Web: http://www.weqas.com http://www.weqas.com |
Laura Lloyd-Lewis
Telefon: 44 (0) 29218 32884 Fax: E-Mail: laura.lloyd-lewis@wales.nhs.uk laura.lloyd-lewis@wales.nhs.uk |
||||||
Haben Sie einen Fehler entdeckt? Bitte wenden Sie sich an den zuständigen EPTIS Koordinator für United Kingdom,
Mr Savvas Xystouris.
Mr Savvas Xystouris.